Clinical Trial

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body's immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma cells.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2021-10-01; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2024-08-07
Trial Details
NCT Number NCT05077527
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center
Conditions AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma +7 more
Enrollment 20 participants
Start Date 2025-02-13
Primary Completion 2028-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10